Drug Trial Radar · NCT06263348
A Post-Marketing Safety Study of Dorzagliatin in Patients With Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,024
Actual
Start
Jan 17, 2024
Primary completion
Dec 31, 2025
Study completion Apr 30, 2026
Sponsor
- Lead sponsor
- Hua Medicine LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- Kun Tuo Xincheng Pharmaceutical Researchand Development(Beijing)Co.,Ltd.
- First posted
- Feb 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the long-term safety of Dorzagliatin in a larger population of type 2 diabetes mellitus patients by collecting the post-marketing clinical safety data of Dorzagliatin.
Conditions
- Type2diabetes
Interventions
Dorzagliatin tabletsDrug
During the study, patients should follow the dosing instructions from the investigator, which are made according to the package insert and the patients' conditions.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidences of ADRs and SAEsTime frame: 52 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.